|
|
|
The field of biomaterials stands as the backbone of the medical device industry. Traditionally the design of biomaterials begins with the development of inert materials that elicit little or no immune responses from the body, followed by the synthesis of a new polymeric material to mimic a naturally occurring biomolecules. However, these approaches returned a relatively small number that have been proven useful in medical devices. Such traditional biomaterials have been constrained by their inability to convey appropriate messages to the cells which surround them - the same messages that are conveyed by proteins in normal human tissues.
|
Kollodis BioSciences has developed new generation of MAPTrix¢â based biomaterials which is designed to be recognized and accepted by human cells, to aid in the natural process of bodily repair (including the healing of tissue and the restoration or augmentation of its form and function), and, ultimately, to promote the regeneration of tissues. The Company believes that the successful realization of these properties will substantially expand the role that artificial devices can play in the prevention and treatment of human disability and disease, and enable the culture of native tissues for successful regeneration.
|
|
